Ultragenyx Pharmaceutical Inc. (FRA:UP0)

Market Cap	1.86B -53.7%
Revenue (ttm)	573.19M +20.1%
Net Income	-489.73M
EPS	-4.97
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	18.50
Previous Close	17.20
Day's Range	18.50 - 18.50
52-Week Range	16.80 - 42.00
Beta	n/a
RSI	42.27
Earnings Date	Feb 13, 2026

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 1,294
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UP0

Financial Performance

In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.13% compared to the previous year's $560.23 million. Losses were -$575.00 million, 1.02% more than in 2024.

Financial numbers in USD